Product Description
Mechanisms of Action: CGRP Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Peripheral Arterial Disease|Ischemic Attack, Transient|Ischemic Stroke|Cerebrovascular Disorders|Coronary Artery Disease|Peripheral Vascular Diseases|Migraine Disorders
Phase 2: Migraine Disorders
Phase 1: Migraine Disorders|Coronary Artery Disease|Myocardial Ischemia|Angina Pectoris|Angina, Stable
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01315847 |
MK-0974-067 | P1 |
Completed |
Migraine Disorders |
2011-07-26 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01294709 |
MK-0974-014 | P1 |
Completed |
Angina Pectoris|Coronary Artery Disease|Myocardial Ischemia|Angina, Stable |
2009-02-28 |
2022-05-04 |
Primary Endpoints |
|
NCT00966030 |
MK0974-042 | P1 |
Completed |
Migraine Disorders |
2008-05-01 |
2022-05-04 |
Primary Endpoints |
|
NCT00965887 |
MK0974-045 | P1 |
Completed |
Migraine Disorders |
2008-05-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01209741 |
NCT01209741 | P1 |
Completed |
Migraine Disorders |
2007-11-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00758836 |
MK-0974-046 | P2 |
Completed |
Migraine Disorders |
2009-08-24 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2008-004095-43 |
Combination Dosing | P2 |
Completed |
Migraine Disorders |
2009-08-24 |
2025-06-28 |
Treatments |
|
NCT00797667 |
NCT00797667 | P2 |
Terminated |
Migraine Disorders |
2009-05-20 |
2022-05-04 |
Primary Endpoints |
|
NCT00246337 |
MK0974-004 | P2 |
Completed |
Migraine Disorders |
2006-05-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2010-019288-13 |
MK0974-065 | P3 |
Completed |
Migraine Disorders |
2011-04-08 |
2022-03-13 |
Treatments |
|
NCT01125774 |
MK-0974-065 | P3 |
Completed |
Migraine Disorders |
2011-04-08 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00662818 |
MK-0974-034 | P3 |
Completed |
Ischemic Attack, Transient|Peripheral Arterial Disease|Ischemic Stroke|Migraine Disorders|Peripheral Vascular Diseases|Cerebrovascular Disorders |
2009-09-02 |
2022-05-04 |
Primary Endpoints |
|
2007-002667-28 |
Acute Treatment of Multiple Migraines With or Without Aura in Adults | P3 |
Completed |
Migraine Disorders |
2009-03-27 |
2022-03-12 |
Treatments |
|
2007-007723-40 |
Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients | P3 |
Completed |
Migraine Disorders|Coronary Artery Disease |
2009-03-25 |
2022-03-12 |
Treatments |
|
NCT00483704 |
MK-0974-031 | P3 |
Completed |
Migraine Disorders |
2009-03-25 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2006-004259-40 |
Long Term Safety Study | P3 |
Completed |
Migraine Disorders |
2009-01-23 |
2022-03-12 |
Treatments |
|
NCT00443209 |
MK-0974-012 | P3 |
Completed |
Migraine Disorders |
2009-01-22 |
2022-05-04 |
Primary Endpoints |
|
2006-006187-35 |
2006-006187-35 | P3 |
Completed |
Migraine Disorders |
2008-01-11 |
2025-05-25 |
Treatments |
|
NCT00432237 |
NCT00432237 | P3 |
Completed |
Migraine Disorders |
2007-12-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00442936 |
MK-0974-011 | P3 |
Completed |
Migraine Disorders |
2007-10-02 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2006-004257-14 |
MK-0974 Pivotal Study 1 - worldwide (with active comparator) | P3 |
Completed |
Migraine Disorders |
2007-10-02 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2024 |
PubMed |
CGRP receptor antagonists (gepants). |
|
07/28/2023 |
PubMed |
Blocking the CGRP Receptor: Differences across Human Vascular Beds. |
|
10/01/2022 |
PubMed |
The CGRP Receptor Antagonist MK0974 Induces EVI1(high) AML Cell Apoptosis by Disrupting ERK Signaling. |
|
06/16/2022 |
News Article |
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine |